OncoMatch/Clinical Trials/NCT05821166
Potential of Moderate Whole Body Hyperthermia to Enhance Response
Is NCT05821166 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies moderate Whole Body Hyperthermia (mWBH) for oncology.
Treatment: moderate Whole Body Hyperthermia (mWBH) — Using moderate whole-body hyperthermia (mWBH) in tumor patients to see the influence on circulating tumor cells, tumor response, quality of life, fatigue, psyche, immune response and tumor microenvironment
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: BRAF wild-type
missing BRAF-V600 mutation
Required: HPV associated
HPV-associated squamous cell carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Grade: high-grade
treatment-naive stage IV with multiple metastases; metastatic or inoperable pancreatic cancer; metastatic high-grade sarcoma; metastatic or loco-regionally recurrent HPV-associated squamous cell carcinoma; metastatic, castration-resistant prostate cancer
Performance status
WHO 0–2
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05821166 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require BRAF?
Yes, BRAF wild-type is a required biomarker for enrollment.
Does this trial require HPV?
Yes, HPV associated is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify